Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal ranibizumab for pigment epithelial detachments secondary to AMD
2008-004675-22Phase 4Completed
- Sponsor
- University of Bonn
- Start
- Sep 2008
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ranibizumab in age-related macular degeneration (AMD) and pigment epithelium detachment (PED), sponsored by University of Bonn. Primary endpoint: Best-corrected visual acuity (ETDRS charts). Started Sep 2008; status: completed.
02
Drugs
ranibizumab
03
Conditions
age-related macular degeneration (AMD)pigment epithelium detachment (PED)
Beyond the preview
Go deeper on 2008-004675-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004675-22.